Investigating how genetic variations in ELAPOR1 and ELAPOR2 affect insulin secretion and glucose regulation
Untersuchung Des Einflusses Von Genetischen Varianten in ELAPOR1 Oder ELAPOR2 Auf Die Insulinsekretion Und Glukoseregulation im Menschen
This study is trying to see how changes in certain genes affect insulin production and blood sugar control in people, which could help improve diabetes treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | University Hospital Tuebingen Academic / other |
| Locations | 1 site (Tübingen) |
| Trial ID | NCT05575206 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the impact of genetic variations in the ELAPOR1 and ELAPOR2 genes on insulin secretion and glucose regulation in humans. Utilizing techniques such as the hyperglycemic glucose clamp and oral glucose tolerance tests, the study will assess how these genetic factors contribute to the pathogenesis of type 2 diabetes. The research is motivated by the recent discovery of a receptor, inceptor, which influences beta cell function and insulin sensitivity. By understanding these genetic influences, the study seeks to uncover potential therapeutic targets for improving diabetes management.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals with genetic variations in the ELAPOR1 and ELAPOR2 genes.
Not a fit: Patients who are pregnant, lactating, or have a history of severe neurological or psychiatric diseases, as well as those with pancreatic diseases or on medications affecting glucose metabolism, may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to new insights into the genetic factors influencing insulin secretion and glucose regulation, potentially guiding personalized treatment strategies for type 2 diabetes.
How similar studies have performed: While this specific investigation into ELAPOR1 and ELAPOR2 is novel, previous studies have shown success in exploring genetic variations related to insulin secretion and diabetes management.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures. * subjects with genetic variations in ELAPOR1 and ELAPOR2 Exclusion Criteria: * Women during pregnancy and lactation * Treatment with any medication effecting on glucose metabolism like anti-diabetic drugs or steroids * Any pancreatic disease * Known current presence or history of severe neurological or psychiatric diseases, schizophrenia, bipolar disorder
Where this trial is running
Tübingen
- University Hopsital Tübingen — Tübingen, Germany (Recruiting)
Study contacts
- Principal investigator: Reiner Jumpertz-von Schwartzenberg, MD — University Hopsital Tübingen
- Study coordinator: Reiner Jumpertz-von Schwartzenberg, MD
- Email: Reiner.Jumpertz-vs@med.uni-tuebingen.de
- Phone: +49 7071 29 68934
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.